---
figid: PMC7395689__OTT-13-7411-g0001
figlink: pmc/articles/PMC7395689/figure/f0001/
number: F1
caption: 'The figure describes the process by which αVβ3 mediates prostate cancer
  cell metastasis. Macroscopically, after cancer cells destroy the ECM and leave their
  primary site, cancer cells depend on αVβ3, which destroys vascular endothelial cells,
  to enter blood vessels. In blood vessels, tumor cells under the protection of BSP
  escape the attack of the immune system and then pass through the blood vessels to
  reach the metastatic site. Here, bone tissue is used as an example. Under the induction
  of VEGF, cancer cells recognize SPARC and HA and interact with them on the surface
  of bone with the help of αVβ3; at the same time, VEGF induces neovascularization
  to supply blood to the cell mass system. At the microscopic level, IL-8, IGF-I,
  CCN2 and other ligands activate different signaling pathways to promote the expression
  of αVβ3 in cancer cells. In addition, CCN2 transmits signals into the cell through
  αVβ3 to increase the acetylation of the transcription factor RUNX2, and RUNX2 promotes
  RANKL expression in tumor cells; these tumor cells then secrete RANKL to induce
  osteoblast differentiation into osteoclasts, and osteoclast-mediated bone tissue
  remodeling can expose HA and SPARC on the bone surface. BKCa and CXCL16 promote
  the aggregation and activation of αVβ3 and trigger the activation of downstream
  FAK. In addition to enhancing the activity of the ERK or PI3K pathway, activated
  FAK triggers cytoskeletal protein remodeling with the help of adaptor proteins,
  further enhancing tumor cell invasion ability. Cell information: The PC-3 cell line
  was initiated from the bone metastasis of a grade IV prostatic adenocarcinoma from
  a 62-year-old Caucasian male; DU145 was initiated from a 69-year-old Caucasian male
  with brain metastasis of prostatic adenocarcinoma; LNCAP was isolated from the left
  supraclavicular lymph node of a 50-year-old prostate cancer patient. LNCAP is sensitive
  to hormones; C4-2B is a subtype derived from the LNCAP cell line.Abbreviations:
  BSP, bone sialoprotein; VEGF, vascular endothelial growth factor; HA, hydroxyapatite;
  SPARC, osteonectin; FAK, focal adhesion kinase; IGF-I, insulin-like growth factor;
  IL-8, interleukin8; OPN, osteopontin; MMP (2 or 9), matrix metalloproteinase (2
  or 9); CCN2, connective tissue growth factor; CCL2, chemokines2; CXCL16, chemokines16;
  P, phosphorylated; AC, acetylated.'
pmcid: PMC7395689
papertitle: 'Role of αVβ3 in Prostate Cancer: Metastasis Initiator and Important Therapeutic
  Target.'
reftext: Lin Tang, et al. Onco Targets Ther. 2020;13:7411-7422.
pmc_ranked_result_index: '88476'
pathway_score: 0.9320436
filename: OTT-13-7411-g0001.jpg
figtitle: Figure describes the process by which AVB3 mediates prostate cancer cell
  metastasis
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7395689__OTT-13-7411-g0001.html
  '@type': Dataset
  description: 'The figure describes the process by which αVβ3 mediates prostate cancer
    cell metastasis. Macroscopically, after cancer cells destroy the ECM and leave
    their primary site, cancer cells depend on αVβ3, which destroys vascular endothelial
    cells, to enter blood vessels. In blood vessels, tumor cells under the protection
    of BSP escape the attack of the immune system and then pass through the blood
    vessels to reach the metastatic site. Here, bone tissue is used as an example.
    Under the induction of VEGF, cancer cells recognize SPARC and HA and interact
    with them on the surface of bone with the help of αVβ3; at the same time, VEGF
    induces neovascularization to supply blood to the cell mass system. At the microscopic
    level, IL-8, IGF-I, CCN2 and other ligands activate different signaling pathways
    to promote the expression of αVβ3 in cancer cells. In addition, CCN2 transmits
    signals into the cell through αVβ3 to increase the acetylation of the transcription
    factor RUNX2, and RUNX2 promotes RANKL expression in tumor cells; these tumor
    cells then secrete RANKL to induce osteoblast differentiation into osteoclasts,
    and osteoclast-mediated bone tissue remodeling can expose HA and SPARC on the
    bone surface. BKCa and CXCL16 promote the aggregation and activation of αVβ3 and
    trigger the activation of downstream FAK. In addition to enhancing the activity
    of the ERK or PI3K pathway, activated FAK triggers cytoskeletal protein remodeling
    with the help of adaptor proteins, further enhancing tumor cell invasion ability.
    Cell information: The PC-3 cell line was initiated from the bone metastasis of
    a grade IV prostatic adenocarcinoma from a 62-year-old Caucasian male; DU145 was
    initiated from a 69-year-old Caucasian male with brain metastasis of prostatic
    adenocarcinoma; LNCAP was isolated from the left supraclavicular lymph node of
    a 50-year-old prostate cancer patient. LNCAP is sensitive to hormones; C4-2B is
    a subtype derived from the LNCAP cell line.Abbreviations: BSP, bone sialoprotein;
    VEGF, vascular endothelial growth factor; HA, hydroxyapatite; SPARC, osteonectin;
    FAK, focal adhesion kinase; IGF-I, insulin-like growth factor; IL-8, interleukin8;
    OPN, osteopontin; MMP (2 or 9), matrix metalloproteinase (2 or 9); CCN2, connective
    tissue growth factor; CCL2, chemokines2; CXCL16, chemokines16; P, phosphorylated;
    AC, acetylated.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - IBSP
  - SPARC
  - SPP1
  - MMP9
  - TNFSF11
  - MMP2
  - IGF1
  - CXCL8
  - CTGF
  - CCL2
  - CXCL16
  - PTK2
  - ACTA1
  - ACTA2
  - ACTG1
  - ACTB
  - ACTC1
  - ACTG2
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - AKT2
  - AKT3
  - AKT1
  - SRC
  - ADCY2
  - ADCY3
  - ADCY5
  - ADCY6
  - ADCY8
  - ADCY9
  - ADCY10
  - ADCY4
  - ADCY1
  - ADCY7
  - SAMD5
  - RUNX2
  - MTOR
  - MAPK3
  - MAPK1
  - IGF1R
  - O
  - prostate cancer
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: BSP
  symbol: BSP
  source: hgnc_alias_symbol
  hgnc_symbol: IBSP
  entrez: '3381'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: SPARC
  symbol: SPARC
  source: hgnc_symbol
  hgnc_symbol: SPARC
  entrez: '6678'
- word: OPN
  symbol: OPN
  source: hgnc_prev_symbol
  hgnc_symbol: SPP1
  entrez: '6696'
- word: MMP-9
  symbol: MMP9
  source: hgnc_symbol
  hgnc_symbol: MMP9
  entrez: '4318'
- word: RANKL
  symbol: RANKL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF11
  entrez: '8600'
- word: MMP-2
  symbol: MMP2
  source: hgnc_symbol
  hgnc_symbol: MMP2
  entrez: '4313'
- word: IGF-I
  symbol: IGF-I
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: IL-8
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: BSP
  symbol: BSP
  source: hgnc_alias_symbol
  hgnc_symbol: IBSP
  entrez: '3381'
- word: CCN2
  symbol: CCN2
  source: hgnc_alias_symbol
  hgnc_symbol: CTGF
  entrez: '1490'
- word: CCL2
  symbol: CCL2
  source: hgnc_symbol
  hgnc_symbol: CCL2
  entrez: '6347'
- word: CXCL16
  symbol: CXCL16
  source: hgnc_symbol
  hgnc_symbol: CXCL16
  entrez: '58191'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA2
  entrez: '59'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG1
  entrez: '71'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: Actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG2
  entrez: '72'
- word: FAK
  symbol: FAK
  source: hgnc_alias_symbol
  hgnc_symbol: PTK2
  entrez: '5747'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: Samd5
  symbol: SAMD5
  source: hgnc_symbol
  hgnc_symbol: SAMD5
  entrez: '389432'
- word: RUNX2
  symbol: RUNX2
  source: hgnc_symbol
  hgnc_symbol: RUNX2
  entrez: '860'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: RUNX2
  symbol: RUNX2
  source: hgnc_symbol
  hgnc_symbol: RUNX2
  entrez: '860'
- word: MMP-9
  symbol: MMP9
  source: hgnc_symbol
  hgnc_symbol: MMP9
  entrez: '4318'
- word: RANKL
  symbol: RANKL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF11
  entrez: '8600'
- word: RUNX2
  symbol: RUNX2
  source: hgnc_symbol
  hgnc_symbol: RUNX2
  entrez: '860'
- word: MMP-2
  symbol: MMP2
  source: hgnc_symbol
  hgnc_symbol: MMP2
  entrez: '4313'
- word: OPN
  symbol: OPN
  source: hgnc_prev_symbol
  hgnc_symbol: SPP1
  entrez: '6696'
- word: IGF-IR
  symbol: IGFIR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
chemicals:
- word: O
  source: MESH
  identifier: D013481
diseases:
- word: prostate cancer
  source: MESH
  identifier: D011471
figid_alias: PMC7395689__F1
redirect_from: /figures/PMC7395689__F1
figtype: Figure
---
